SequelSEC

EXICURE, INC. XCUR

Pharmaceutical Preparations · CIK 0001698530 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$7.34M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$16.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.57Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity4.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio1.19x18th

EXICURE, INC. (XCUR) reported revenue of $0 and net income of -$8.28M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from EXICURE, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

EXICURE, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$7.34M
Net income-$8.28M
Research & development$2.03M
Weighted-average diluted sharesUnavailable
Pretax income-$8.92M
Income tax expense-$634.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$5.28M
Selling & marketingUnavailable

Balance

EXICURE, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$11.40M
Current assets$2.32M
Total liabilities$10.42M
Current liabilities$4.17M
Total equity incl. NCI$977.00K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$4.40M
Long-term debtUnavailable
Accounts payable$2.18M

Cash flow

EXICURE, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$6.70M
Capital expendituresUnavailable
Investing cash flow$563.00K
Financing cash flow$0
Net change in cash-$6.14M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$199.00K

Derived

EXICURE, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.56x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XCUR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-29View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-06-27View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.